HRP940175A2 - Nucleic acid pharmaceuticals - Google Patents
Nucleic acid pharmaceuticalsInfo
- Publication number
- HRP940175A2 HRP940175A2 HR08/089,985A HRP940175A HRP940175A2 HR P940175 A2 HRP940175 A2 HR P940175A2 HR P940175 A HRP940175 A HR P940175A HR P940175 A2 HRP940175 A2 HR P940175A2
- Authority
- HR
- Croatia
- Prior art keywords
- nucleic acid
- acid pharmaceuticals
- pharmaceuticals
- nucleic
- acid
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3238393A | 1993-03-18 | 1993-03-18 | |
| US8998593A | 1993-07-08 | 1993-07-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP940175A2 true HRP940175A2 (en) | 1997-04-30 |
Family
ID=26708344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR08/089,985A HRP940175A2 (en) | 1993-03-18 | 1994-03-17 | Nucleic acid pharmaceuticals |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0620277A1 (xx) |
| JP (2) | JP2812352B2 (xx) |
| CN (1) | CN1119458A (xx) |
| AU (1) | AU676258B2 (xx) |
| BG (1) | BG63126B1 (xx) |
| BR (1) | BR9406007A (xx) |
| CA (1) | CA2119175A1 (xx) |
| CZ (1) | CZ290315B6 (xx) |
| DZ (1) | DZ1759A1 (xx) |
| FI (1) | FI954329A (xx) |
| HR (1) | HRP940175A2 (xx) |
| HU (1) | HUT73397A (xx) |
| IL (1) | IL108915A0 (xx) |
| NO (1) | NO953649L (xx) |
| NZ (1) | NZ263680A (xx) |
| PL (1) | PL178626B1 (xx) |
| RO (1) | RO117710B1 (xx) |
| SI (1) | SI9420014A (xx) |
| SK (1) | SK114295A3 (xx) |
| UA (1) | UA42715C2 (xx) |
| WO (1) | WO1994021797A1 (xx) |
| YU (1) | YU12894A (xx) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849719A (en) * | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
| US6911216B1 (en) | 1994-10-12 | 2005-06-28 | Genzyme Corporation | Targeted delivery via biodegradable polymers |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| DE19512142A1 (de) * | 1995-03-31 | 1996-10-02 | Immuno Ag | Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält |
| US6019980A (en) | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| US6017897A (en) * | 1995-06-07 | 2000-01-25 | Pasteur Merieux Connaught Canada | Nucleic acid respiratory syncytial virus vaccines |
| US6083925A (en) * | 1995-06-07 | 2000-07-04 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
| FR2751225B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
| US6204250B1 (en) | 1996-11-22 | 2001-03-20 | The Mount Sinai Medical Center Of The City Of New York | Immunization of infants |
| EP1017283B1 (en) * | 1997-02-14 | 2004-12-15 | Merck & Co., Inc. | Polynucleotide vaccine formulations |
| US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
| UA78180C2 (uk) | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
| FR2772047B1 (fr) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
| CA2340330A1 (en) | 1998-08-20 | 2000-03-02 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein c of chlamydia |
| US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
| US6693087B1 (en) | 1998-08-20 | 2004-02-17 | Aventis Pasteur Limited | Nucleic acid molecules encoding POMP91A protein of Chlamydia |
| US6881723B1 (en) | 1998-11-05 | 2005-04-19 | Powderject Vaccines, Inc. | Nucleic acid constructs |
| US7691389B2 (en) | 1998-12-22 | 2010-04-06 | Pfizer Inc | Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof |
| US7618797B2 (en) | 1998-12-22 | 2009-11-17 | Pfizer Inc | Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof |
| AU3593200A (en) | 1999-02-09 | 2000-08-29 | Powderject Vaccines, Inc. | (mycobacterium tuberculosis), immunization |
| US6943152B1 (en) | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
| JP2001151698A (ja) * | 1999-09-10 | 2001-06-05 | Nichiko Pharmaceutical Co Ltd | インフルエンザワクチン |
| WO2001030847A1 (en) | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
| US7196066B1 (en) | 1999-11-03 | 2007-03-27 | Powderject Vaccines, Inc. | DNA-vaccines based on constructs derived from the genomes of human and animal pathogens |
| US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
| US7078388B2 (en) | 2000-01-21 | 2006-07-18 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
| EP1792995A3 (en) | 2000-05-08 | 2007-06-13 | Sanofi Pasteur Limited | Chlamydia secretory locus orf and uses thereof |
| AU5810201A (en) | 2000-05-10 | 2001-11-20 | Aventis Pasteur | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
| AU2005248361B2 (en) | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
| US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| WO2008150998A1 (en) * | 2007-05-31 | 2008-12-11 | Becton, Dickinson And Company | Sequences and methods for detecting influenza a and influenza b virus |
| US8354230B2 (en) * | 2007-12-21 | 2013-01-15 | Quest Diagnostics Investments Inc. | Multiplex detection assay for influenza and RSV viruses |
| CN102170902B (zh) | 2008-08-01 | 2015-07-15 | 伽玛疫苗有限公司 | 流感疫苗 |
| WO2010127252A2 (en) * | 2009-04-30 | 2010-11-04 | Vanderbilt University | Monoclonal antibodies to influenza h1n1 virus and uses thereof |
| SG168423A1 (en) * | 2009-07-13 | 2011-02-28 | Agency Science Tech & Res | Influenza detection method and kit therefor |
| TWI627281B (zh) | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物 |
| AR083533A1 (es) | 2010-10-22 | 2013-03-06 | Boehringer Ingelheim Vetmed | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe |
| AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
| WO2013033092A2 (en) | 2011-09-03 | 2013-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Streptococcus suis pilus antigens |
| US10383835B2 (en) | 2012-03-14 | 2019-08-20 | The Regents Of The University Of California | Treatment of inflammatory disorders in non-human mammals |
| WO2014127825A1 (en) | 2013-02-21 | 2014-08-28 | Boehringer Ingelheim Vetmedica Gmbh | H5 proteins of h5n1 influenza virus for use as a medicament |
| JP2016520534A (ja) * | 2013-03-18 | 2016-07-14 | イマクシオＩｍａｘｉｏ | インフルエンザ核タンパク質ワクチン |
| WO2015048115A1 (en) | 2013-09-25 | 2015-04-02 | Zoetis Llc | Pcv2b divergent vaccine composition and methods of use |
| AU2015241107B2 (en) | 2014-04-03 | 2019-10-03 | Boehringer Ingelheim Animal Health USA Inc. | Porcine epidemic diarrhea virus vaccine |
| ES2778649T3 (es) | 2015-08-31 | 2020-08-11 | Boehringer Ingelheim Vetmedica Gmbh | Vacunas pestivirales para temblores congénitos |
| MX2018003173A (es) | 2015-09-16 | 2018-05-17 | Boehringer Ingelheim Vetmedica Inc | Vacunas de salmonella choleraesuis-salmonella typhimurium. |
| AR109540A1 (es) | 2016-09-20 | 2018-12-19 | Boehringer Ingelheim Vetmedica Gmbh | Moléculas promotoras para expresar antígenos virales |
| EP3515480A1 (en) | 2016-09-20 | 2019-07-31 | Boehringer Ingelheim Vetmedica GmbH | New swine influenza vaccine |
| CN109715204B (zh) | 2016-09-20 | 2023-08-22 | 勃林格殷格翰动物保健有限公司 | 新的ehv插入位点orf70 |
| TW201823467A (zh) | 2016-09-20 | 2018-07-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 犬腺病毒載體 |
| WO2018083154A1 (en) | 2016-11-03 | 2018-05-11 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine against porcine parvovirus |
| MY191895A (en) | 2016-11-03 | 2022-07-18 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof |
| JP2020506915A (ja) | 2017-01-30 | 2020-03-05 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | ブタコロナウイルスワクチン |
| WO2019014144A1 (en) | 2017-07-12 | 2019-01-17 | Boehringer Ingelheim Vetmedica, Inc. | IMMUNOGENIC COMPOSITIONS BASED ON SENECAVIRUS TYPE A AND CORRESPONDING METHODS |
| CA3072553A1 (en) | 2017-09-23 | 2019-03-28 | Boehringer Ingelheim Vetmedica Gmbh | Paramyxoviridae expression system |
| WO2019092027A1 (en) | 2017-11-09 | 2019-05-16 | Boehringer Ingelheim Vetmedica Gmbh | Sapelovirus immunogenic compositions and uses thereof |
| AU2019223768A1 (en) | 2018-02-23 | 2020-08-27 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom |
| CA3091960A1 (en) | 2018-03-19 | 2019-09-26 | Boehringer Ingelheim Vetmedica Gmbh | New ehv insertion site ul43 |
| AR115002A1 (es) | 2018-03-19 | 2020-11-18 | Boehringer Ingelheim Vetmedica Gmbh | Ehv con ul18 y/o ul8 inactivados |
| JP7162072B2 (ja) | 2018-03-26 | 2022-10-27 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | 免疫原性組成物を製造する方法 |
| CN112867506A (zh) | 2018-09-20 | 2021-05-28 | 勃林格殷格翰动物保健有限公司 | 抗猪流行性腹泻的鼻内载体疫苗 |
| EP3852797A1 (en) | 2018-09-20 | 2021-07-28 | Boehringer Ingelheim Vetmedica GmbH | Modified pedv spike protein |
| IT201900007060A1 (it) | 2019-05-21 | 2020-11-21 | St Superiore Di Sanita | Cellule tumorali ingegnerizzate e loro usi |
| IT201900012540A1 (it) | 2019-07-22 | 2021-01-22 | Humanitas Mirasole Spa | Inibitori di CHI3L1 e loro usi |
| EP4100420A1 (en) | 2020-02-06 | 2022-12-14 | Boehringer Ingelheim Vetmedica GmbH | Polypeptides useful for detecting anti-rhabdovirus antibodies |
| WO2022076979A1 (en) | 2020-10-05 | 2022-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Fusion protein useful for vaccination against rotavirus |
| WO2022076977A1 (en) | 2020-10-05 | 2022-04-14 | Boehringer Ingelheim Animal Health USA Inc. | Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof |
| US20240050555A1 (en) | 2022-04-05 | 2024-02-15 | Boehringer Ingelheim Vetmedica Gmbh | Immunogenic composition useful for vaccination against rotavirus |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL86354A0 (en) * | 1987-05-22 | 1988-11-15 | Orion Yhtymae Oy | Episomal vector for the expression of selected dna fragments coding for optional polypeptides in mammalian cells and methods for the production thereof |
| WO1990011092A1 (en) * | 1989-03-21 | 1990-10-04 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
-
1994
- 1994-03-09 IL IL10891594A patent/IL108915A0/xx unknown
- 1994-03-09 EP EP94200605A patent/EP0620277A1/en not_active Withdrawn
- 1994-03-14 HU HU9502702A patent/HUT73397A/hu unknown
- 1994-03-14 SK SK1142-95A patent/SK114295A3/sk unknown
- 1994-03-14 SI SI9420014A patent/SI9420014A/sl not_active IP Right Cessation
- 1994-03-14 BR BR9406007A patent/BR9406007A/pt not_active Application Discontinuation
- 1994-03-14 WO PCT/US1994/002751 patent/WO1994021797A1/en active IP Right Grant
- 1994-03-14 CN CN94191485A patent/CN1119458A/zh active Pending
- 1994-03-14 UA UA95094152A patent/UA42715C2/uk unknown
- 1994-03-14 NZ NZ263680A patent/NZ263680A/en unknown
- 1994-03-14 CZ CZ19952373A patent/CZ290315B6/cs not_active IP Right Cessation
- 1994-03-14 RO RO95-01622A patent/RO117710B1/ro unknown
- 1994-03-14 PL PL94310677A patent/PL178626B1/pl unknown
- 1994-03-16 CA CA002119175A patent/CA2119175A1/en not_active Abandoned
- 1994-03-16 DZ DZ940021A patent/DZ1759A1/fr active
- 1994-03-17 AU AU57889/94A patent/AU676258B2/en not_active Ceased
- 1994-03-17 HR HR08/089,985A patent/HRP940175A2/xx not_active Application Discontinuation
- 1994-03-17 YU YU12894A patent/YU12894A/sh unknown
- 1994-03-18 JP JP6049102A patent/JP2812352B2/ja not_active Expired - Fee Related
-
1995
- 1995-09-14 FI FI954329A patent/FI954329A/fi unknown
- 1995-09-15 NO NO953649A patent/NO953649L/no not_active Application Discontinuation
- 1995-09-18 BG BG100006A patent/BG63126B1/bg unknown
-
1997
- 1997-10-22 JP JP29013797A patent/JP3608642B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0620277A1 (en) | 1994-10-19 |
| CA2119175A1 (en) | 1994-09-19 |
| NO953649D0 (no) | 1995-09-15 |
| NO953649L (no) | 1995-11-17 |
| CZ237395A3 (en) | 1996-02-14 |
| YU12894A (sh) | 1997-12-05 |
| SI9420014A (en) | 1996-08-31 |
| FI954329A0 (fi) | 1995-09-14 |
| UA42715C2 (uk) | 2001-11-15 |
| BR9406007A (pt) | 1996-01-02 |
| NZ263680A (en) | 1997-05-26 |
| SK114295A3 (en) | 1996-02-07 |
| FI954329A (fi) | 1995-09-14 |
| DZ1759A1 (fr) | 2002-02-17 |
| HUT73397A (en) | 1996-07-29 |
| BG100006A (bg) | 1996-12-31 |
| CZ290315B6 (cs) | 2002-07-17 |
| JPH10113194A (ja) | 1998-05-06 |
| PL310677A1 (en) | 1995-12-27 |
| HU9502702D0 (en) | 1995-11-28 |
| RO117710B1 (ro) | 2002-06-28 |
| IL108915A0 (en) | 1994-06-24 |
| AU5788994A (en) | 1994-09-22 |
| BG63126B1 (bg) | 2001-04-30 |
| CN1119458A (zh) | 1996-03-27 |
| AU676258B2 (en) | 1997-03-06 |
| JPH0795888A (ja) | 1995-04-11 |
| JP2812352B2 (ja) | 1998-10-22 |
| JP3608642B2 (ja) | 2005-01-12 |
| WO1994021797A1 (en) | 1994-09-29 |
| PL178626B1 (pl) | 2000-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP940175A2 (en) | Nucleic acid pharmaceuticals | |
| GB9301660D0 (en) | Pharmaceuticals | |
| GB9312348D0 (en) | Pharmaceuticals | |
| AP9400626A0 (en) | Pharmaceuticals | |
| GB9321811D0 (en) | Pharmaceuticals | |
| GB9410170D0 (en) | Nucleic acid | |
| GB9321812D0 (en) | Pharmaceuticals | |
| GB9320316D0 (en) | Pharmaceuticals | |
| AP9400684A0 (en) | Pharmaceuticals | |
| GB9303340D0 (en) | Pharmaceuticals | |
| ZA941885B (en) | Nucleic acid pharmaceuticals | |
| GB9424710D0 (en) | Nucleic acid | |
| GB9310489D0 (en) | Nucleic acid | |
| GB9321394D0 (en) | Pharmaceuticals | |
| GB9326177D0 (en) | Pharmaceuticals | |
| GB9306291D0 (en) | Nucleic acid support | |
| GB9224386D0 (en) | Nucleic acid sequence | |
| GB9226165D0 (en) | Nucleic acid sequence | |
| GB9309643D0 (en) | Pharmaceuticals | |
| GB9320770D0 (en) | Pharmaceuticals | |
| GB9310776D0 (en) | Pharmaceuticals | |
| GB9301881D0 (en) | Pharmaceuticals | |
| GB9310195D0 (en) | Pharmaceuticals | |
| GB9305138D0 (en) | Pharmaceuticals | |
| GB9305141D0 (en) | Pharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| OBST | Application withdrawn |